Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Currently, several FDA-approved agents treat BCG-unresponsive carcinoma in situ (CIS), with or without papillary disease. Pembrolizumab, a single-agent checkpoint inhibitor, has a complete response ...

Elterman noted that the interest in FITs is only going to continue to grow. “We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of ...

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...

Improving Clinical Trial Diversity Key Themes: A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

Bedke explained, “I think the important message is that we have no specific subgroup which will have a more pronounced benefit of EV+P if compared to the platinum-based chemotherapy. Selecting ...